-
Fernandez logs record lap at Indonesia MotoGP practice
-
'I completely trust the club,' says Man City boss Maresca
-
Navi Pillay: S.Africa's global rights activist and Nobel winner
-
'10 out of 10' Quintana reminisces over dream Vuelta win
-
Ufunded Launches “Spotlight” Series, Documenting the Minds Shaping Modern Trading
-
Maddinson given shock recall but fails to score
-
Russell goes fastest in practice for smoggy Singapore GP
-
Navi Pillay, South African rights champion, wins Nobel Peace Prize
-
For exiled Russian director Zvyagintsev, triumph without belonging
-
Saudi Arabia says three killed at airport as Yemen war expands
-
Home hope Zheng storms into China Open semi-finals
-
Everton's US owners mull sale of club two years after takeover
-
Zverev churns out win in Shanghai Masters opener
-
Ukraine takes Russia fight to 'scorching sands' of Sahel
-
Hurricane Isaias strengthens en route to US Gulf Coast
-
Chinese AI tool pulled to prevent 'misuse' after South Korea hacks
-
US activists deploy poll volunteers over Trump intimidation fears
-
Asian stocks mostly up as traders weigh AI, oil dips after surge
-
Saint Laurent designer Vaccarello leaves after glittering decade
-
Walking through flames: orangutans rescued in Indonesia fires
-
'Tough to stay here': Nepal flood survivors wait for homes
-
LeBron shines in pre-season debut for re-tooled 76ers
-
Malaysia closes schools in capital, parts of country due to haze
-
Okinawa resolution calls for revision of US forces pact after murder
-
Buccaneers stun Cowboys for first win of NFL season
-
Verdict expected Friday in Mexico trial over murders of Australia, US surfers
-
Activists hope trial will stop 'forever chemicals' at Italy plant
-
New York mayor says asking Trump to withdraw ICE after shooting
-
Guardians rally for 9-5 victory over White Sox to stay alive in MLB playoffs
-
Walking through flames: orangutan rescued in Indonesia fires
-
Asian stocks mixed amid AI concerns, oil dips after surge
-
James shines in pre-season debut for re-tooled 76ers
-
Wallabies expect fast-paced All Blacks in Bledisloe opener
-
Fuel, fertilizer costs strain US farmers' support for Republicans in midterms
-
Tech scammer Elizabeth Holmes focus of documentary by absurdist Nathan Fielder
-
Trump's 'super intelligence' rebrand to sell AI faces uphill battle
-
Climate hopes shift from politics to the courts
-
Fiji demands US provide evidence Chinese official paid bribes for Beijing
-
Will Nobel Peace Prize pick make waves at the White House?
-
More than just football: How scandal-tainted City led Manchester's rebirth
-
Trump rules out new Iran attack before US midterm elections
-
Record Eden Park streak creates tension for All Blacks
-
Far-right influencer shows Israel's coarse political turn
-
EU trade chief seeks 'tangible outcomes' in China talks
-
Seals and sea lions get hearing tested at Australia zoo
-
Man City face Anfield cauldron after guilty Premier League verdicts
-
Mourinho's Real Madrid playing catch-up in Clasico countdown
-
CNN, MS Now, Politico urge judge to extend White House access
-
Joy as USS Lincoln back home after troubled Gulf deployment
-
Trump administration to launch new vaccine research center
Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.
The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.
His next quests include, among others, developing a vaccine against all future coronaviruses.
"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.
"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."
- Twin breakthroughs-
The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.
But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.
"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.
In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.
"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.
"We sat there staring at our phones for five years, and they never rang!"
With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."
Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.
- Helping people -
Weissman grew up in Lexington, Massachusetts.
His father and mother, both since retired, were an engineer and dental hygienist, respectively.
"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.
He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.
As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.
Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.
"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.
Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.
Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.
Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.
Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.
G.AbuHamad--SF-PST